American Journal of Cardiovascular Drugs
Scope & Guideline
Exploring Innovations in Cardiovascular Therapy
Introduction
Aims and Scopes
- Pharmacotherapy for Cardiovascular Diseases:
The journal primarily emphasizes studies related to pharmacological treatments for various cardiovascular conditions, including heart failure, myocardial infarction, and arrhythmias. - Meta-analyses and Systematic Reviews:
A significant portion of the publications includes meta-analyses and systematic reviews that synthesize existing research to provide comprehensive insights into treatment efficacy and safety. - Real-World Evidence:
The journal publishes studies utilizing real-world data to assess the effectiveness and safety of cardiovascular drugs in everyday clinical practice, highlighting the practical implications of therapeutic choices. - Emerging Therapies and Novel Agents:
Research on new and emerging pharmacological agents for cardiovascular conditions is a key focus, showcasing advancements in drug development and innovative treatment strategies. - Guideline-Directed Therapy:
The journal emphasizes the importance of guideline-directed medical therapy, discussing strategies to optimize treatment adherence and improve patient outcomes.
Trending and Emerging
- SGLT2 Inhibitors and GLP-1 Receptor Agonists:
There is a marked increase in studies focusing on the cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists, particularly in patients with heart failure and diabetes, showcasing their role in cardio-protection. - Real-World Data Analyses:
An emerging trend is the utilization of real-world data analyses to evaluate treatment outcomes, adherence, and healthcare resource utilization, providing insights that complement randomized controlled trials. - Pharmacogenomics and Personalized Medicine:
Research into pharmacogenomics and its application in personalized medicine is gaining traction, highlighting the importance of tailoring cardiovascular therapies to individual patient characteristics. - Novel Antithrombotic Strategies:
There is a rising interest in novel antithrombotic strategies and combination therapies, particularly in the context of high-risk patients and those with complex comorbidities. - Health Economics and Cost-Effectiveness:
Increasingly, studies evaluating the cost-effectiveness of cardiovascular therapies are appearing, reflecting a growing emphasis on the economic implications of treatment choices in healthcare.
Declining or Waning
- Traditional Anticoagulation Strategies:
Research focusing on traditional anticoagulants, such as warfarin, is becoming less frequent as newer direct oral anticoagulants (DOACs) gain prominence in clinical practice. - Long-term Outcomes of Older Medications:
Studies examining the long-term outcomes of older medications such as digoxin and certain beta-blockers are declining, as the focus shifts toward newer agents with better efficacy and safety profiles. - Single-Agent Therapies:
There is a noticeable decrease in publications centered around single-agent therapies, as combination therapies and multifactorial approaches gain attention for their enhanced effectiveness.
Similar Journals
Expert Review of Cardiovascular Therapy
Advancing Cardiovascular Insights for Better Patient OutcomesExpert Review of Cardiovascular Therapy is a leading academic journal published by TAYLOR & FRANCIS INC, focusing on innovative and impactful research in the field of cardiovascular medicine. With an ISSN of 1477-9072 and an E-ISSN of 1744-8344, this journal serves as an essential resource for researchers, clinicians, and educators, offering a platform for the dissemination of critical advancements in cardiovascular therapy and internal medicine. Since its inception in 2003, the journal has maintained a reputable standing with a Q2 ranking in various categories including Cardiology and Cardiovascular Medicine, reflecting its influence and rigor in the field. The journal, which is based in the United Kingdom, does not currently offer Open Access options, ensuring that its content is accessible primarily to subscribers. With its commitment to high-quality, peer-reviewed articles, Expert Review of Cardiovascular Therapy is dedicated to bridging the gap between experimental research and clinical application, thereby enhancing patient care and therapeutic outcomes in cardiovascular health.
VASCULAR PHARMACOLOGY
Elevating the standards of vascular pharmacological research.Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.
Journal of Cardiovascular Medicine
Innovating Heart Health Through Groundbreaking StudiesWelcome to the Journal of Cardiovascular Medicine, a leading platform for the dissemination of high-quality research in the field of cardiology and cardiovascular medicine. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an ISSN of 1558-2027 and an E-ISSN of 1558-2035, reflecting its commitment to accessible and innovative cardiovascular research. With a significant impact factor and ranked Q2 in both Cardiology and Cardiovascular Medicine as well as in Medicine (Miscellaneous) for 2023, the journal is recognized for its contributions to advancing knowledge and practice in this critical area of health. The journal disseminates original research, reviews, and clinical studies, aimed at clinicians, researchers, and healthcare professionals who are dedicated to improving cardiovascular health outcomes. With a continuous commitment to evolving research from 2006 to 2024, the journal is an essential resource for those looking to stay at the forefront of the latest discoveries and methodologies in cardiovascular medicine.
CARDIOLOGY CLINICS
Exploring the forefront of cardiovascular medicine since 1983.CARDIOLOGY CLINICS is a prestigious journal published by W B SAUNDERS CO-ELSEVIER INC, offering insightful and comprehensive reviews in the field of cardiology and cardiovascular medicine since its inception in 1983. With its ISSN 0733-8651 and E-ISSN 1558-2264, the journal has established a significant impact factor within the academic community, holding a Q2 ranking in both Cardiology and Cardiovascular Medicine as well as in Medicine (miscellaneous) for 2023. Located in the heart of Philadelphia, USA, it serves as a vital resource for researchers, clinicians, and students seeking to deepen their understanding of cardiovascular diseases and advancements in treatment. Although it operates under a traditional subscription model, the journal remains committed to disseminating valuable knowledge that shapes current practices and informs future research directions. As it converges towards its 2024 issues, CARDIOLOGY CLINICS continues to play an influential role in enhancing the discourse on cardiovascular health worldwide, ensuring that its audience stays at the forefront of clinical and scientific developments.
Netherlands Heart Journal
Advancing Cardiovascular Knowledge for a Healthier TomorrowNetherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.
Journal fur Kardiologie
Pioneering Insights in Cardiology and Cardiovascular Medicine.The Journal fur Kardiologie, published by KRAUSE & PACHERNEGG GMBH, is a pivotal resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 1024-0098 and an E-ISSN of 1680-936X, this journal has played a significant role in disseminating valuable research and clinical studies from 1998 until its coverage discontinuation in Scopus in 2017. Despite its Scopus rank being relatively low at #316/324 in its category, it continues to serve as a platform for emerging cardiology research. The journal’s scope encompasses various aspects of cardiovascular health, providing insights that are crucial for researchers, professionals, and students alike seeking to advance their knowledge and practice in cardiology. While the journal is not open access, its contributions to the field are essential for those looking to stay informed about the latest developments in cardiovascular medicine.
KARDIOLOGIYA
Pioneering Research in Heart HealthKARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.
CIRCULATION JOURNAL
Connecting Global Insights in Cardiology and Medicine.CIRCULATION JOURNAL, published by the Japanese Circulation Society, stands as a premier platform for cutting-edge research in the fields of Cardiology and Cardiovascular Medicine. With an impressive impact factor placing it in the Q1 quartile for both cardiology and general medicine, this journal is essential for researchers and practitioners seeking to stay at the forefront of cardiovascular science. The journal's accessible open access options ensure that groundbreaking studies are widely disseminated, reflecting its commitment to advancing medical knowledge and improving patient care. Since its inception in 1996, CIRCULATION JOURNAL has fostered a global dialogue on vital cardiovascular issues, making it a vital resource for academics, healthcare professionals, and students alike. With its base in Tokyo, Japan, the journal not only highlights regional advancements but also contributes significantly to the global medical community.
Cardiology in Review
Pioneering reviews that shape cardiovascular care.Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
Advancing cardiovascular care through innovative pharmacology.The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.